<DOC>
	<DOCNO>NCT00002111</DOCNO>
	<brief_summary>To investigate toxicity , antiviral activity , pharmacokinetics HIV-infected patient receive 16 week oral saquinavir mesylate ( Ro 31-8959 ) one two dos .</brief_summary>
	<brief_title>A Dose-Escalating Study Ro 31-8959 ( HIV Protease Inhibitor ) Patients With HIV Disease .</brief_title>
	<detailed_description>Cohorts 16 patient receive 1 2 dos Ro 31-8959 20 week . Administration high dose proceed 2-week safety data first eight patient low dose review .</detailed_description>
	<mesh_term>HIV Infections</mesh_term>
	<mesh_term>Acquired Immunodeficiency Syndrome</mesh_term>
	<mesh_term>Protease Inhibitors</mesh_term>
	<mesh_term>Saquinavir</mesh_term>
	<mesh_term>HIV Protease Inhibitors</mesh_term>
	<criteria>Inclusion Criteria Patients must : Documented HIV infection . CD4 count 200 500 cells/mm3 . No evidence viral resistance . HIV RNA quantifiable PCR . Negativity HBsAg , HBeAg , antiHBc . NOTE : Fifty percent patient must measurable p24 antigen level ( &gt; 31 pg/ml ) . Exclusion Criteria Coexisting Condition : Patients follow symptoms condition exclude : Active opportunistic infection require immediate treatment , tuberculosis , cytomegalovirus , cerebral toxoplasmosis , Pneumocystis carinii pneumonia . Unable maintain adequate oral intake . Clinically significant vomit and/or diarrhea . Malignancy , visceral Kaposi 's sarcoma , lymphoma require systemic chemotherapy within next 12 month . Unable comply protocol requirement , judgment investigator . Any grade 3 bad laboratory clinical abnormality . Concurrent Medication : Excluded : Antineoplastic agent . Concomitant maintenance treatment exclude experimental drug drug know nephrotoxic hepatotoxic potential . Concurrent Treatment : Excluded : Radiation therapy local skin radiation therapy . Patients follow prior condition exclude : Unexplained temperature &gt; = 38.5 C ( 101.5 F ) persist 14 day within 30day period . Unexplained , chronic diarrhea persist 14 day within 30day period . Prior Medication : Excluded : Prior treatment HIV proteinase inhibitor . AZT within 30 day prior study entry OR last 1 year . Other antiretroviral therapy ( besides AZT ) within 30 day prior study entry OR last 14 day . Acute therapy opportunistic infection within 14 day prior study entry .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>May 1995</verification_date>
	<keyword>AIDS-Related Complex</keyword>
	<keyword>Saquinavir</keyword>
	<keyword>HIV Protease Inhibitors</keyword>
</DOC>